S&P 500
7,755.40
+0.25%
Dow Jones
53,854.00
+0.06%
Nasdaq 100
29,806.00
+0.82%
Russell 2000
3,043.07
+0.48%
FTSE 100
10,834.00
+0.00%
Nikkei 225
68,490.70
+1.95%
Innovative Industrial Properties

Innovative Industrial Properties (IIPR) Q2 2026 Earnings

Reported Aug 3, 2026 at 4:13 PM ET · SEC Source

Q2 26 EPS

$1.36

BEAT +32.68%

Est. $1.03

Q2 26 Revenue

$63.3M

MISS 6.87%

Est. $68.0M

Did IIPR Beat Earnings? Q2 2026 Results

Innovative Industrial Properties delivered a sharply mixed second quarter, posting earnings that cleared the bar by a wide margin while revenue fell short of expectations. The cannabis-focused REIT reported Q2 2026 adjusted EPS of $1.36, beating the … Read more Innovative Industrial Properties delivered a sharply mixed second quarter, posting earnings that cleared the bar by a wide margin while revenue fell short of expectations. The cannabis-focused REIT reported Q2 2026 adjusted EPS of $1.36, beating the $1.02 consensus estimate by 32.68%, even as revenue of $63.31 million trailed the $67.98 million analyst forecast by 6.87%, rising just 0.7% year over year. The earnings strength was driven largely by an $11.85 million net gain on real estate sales, including the $88.50 million disposal of a New York property, and an $8.50 million contribution from the company's newly completed $270 million strategic investment in life sciences platform IQHQ, which now accounts for 12.2% of annualized base rent and interest income. Tenant credit pressures cloud the outlook, with Parallel newly disclosed as in default on $1.6 million in July rent and 4Front's four properties awaiting receivership resolution expected by year-end 2026 or early 2027; management is leaning on approximately $300 million in total liquidity and conservative leverage of 1.7x net debt to adjusted EBITDA to pursue accretive opportunities as the U.S. Cannabis market expands.

Key Takeaways

  • • New leases executed on existing properties and annual contractual rent escalations
  • • $8.5 million interest and dividend income from IQHQ life science investments
  • • $16.7 million gain on sale of Perth, New York property for $88.5 million
  • • Security deposit applications of $1.2 million from Battle Green and The Cannabist Company
  • • Seller-financed note interest income from Perth, NY property sale

IIPR Forward Guidance & Outlook

IIP expects to pursue accretive growth opportunities leveraging its approximately $300 million in total liquidity, conservative leverage, and demonstrated access to multiple capital sources. The company is working toward transferring cannabis licenses at PharmaCann's New York and Pennsylvania properties to new tenants in the near-term. Tentative arrangements with prospective new tenants for 4Front's four assets (totaling approximately 488,000 square feet) are expected to go into effect following receivership proceedings anticipated by year-end 2026 or early 2027. Management is shifting the revenue mix toward life sciences, with the IQHQ investment now fully funded. The U.S. cannabis market is projected to grow at an 8% CAGR from 2025 to 2030, reaching an estimated $43 billion in legal sales by 2030, supported by the April 2026 reclassification of medical cannabis to Schedule III.

24/7 Wall St

IIPR YoY Financials

Q2 2026 vs Q2 2025, source: SEC Filings

24/7 Wall St

IIPR Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q4 25

“Our second quarter activity reflects the continued execution of our strategy across multiple fronts by our management team. We completed the funding of our $270 million investment in IQHQ, generated meaningful leasing momentum across our portfolio and proactively strengthened our balance sheet through a series of successful capital markets transactions.”

— Alan Gold, Q2 2026 Earnings Press Release

Back to IIPR Stock Page